Trial Outcomes & Findings for Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder (NCT NCT03526354)
NCT ID: NCT03526354
Last Updated: 2025-05-23
Results Overview
The Timeline Follow Back (TLFB) scale is used to measure weekly substance use for alcohol, marijuana, cocaine, and/or heroin by assessing the number of days a person used substances in the past week, on a scale from 0 to 7 \[0 = no substances that week; 7 = substance use every day\]. The outcome measure was the number of days per week that participants used a substance. If participants use more than one substance, only the primary substance (one used mostly frequently) was analyzed. While the TLFB was assessed weekly, the outcome measure reported is the change in substance use between Week 0 (Baseline) and Week 12 (End of Study). A decrease in number of days/week that substances were used indicates an improved (better) outcome. While the TLFB was assessed weekly, the outcome measure reported is the change in substance use between Week 0 (Baseline) and Week 12 (End of Study). A decrease in number of days/week that substances were used indicates an improved (better) outcome.
COMPLETED
PHASE4
50 participants
12 weeks
2025-05-23
Participant Flow
Participant milestones
| Measure |
Experimental
Brexpiprazole 4mg daily for 12 weeks
Brexpiprazole: Brexpiprazole 4mg daily for 12 weeks
|
Treatment as Usual
Stay on current antipsychotic medication for 12 weeks
Treatment as Usual: Current antipsychotic medication for 12 weeks
|
|---|---|---|
|
Overall Study
STARTED
|
21
|
18
|
|
Overall Study
COMPLETED
|
15
|
14
|
|
Overall Study
NOT COMPLETED
|
6
|
4
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder
Baseline characteristics by cohort
| Measure |
Experimental
n=21 Participants
Brexpiprazole 4mg daily for 12 weeks
Brexpiprazole: Brexpiprazole 4mg daily for 12 weeks
|
Treatment as Usual
n=18 Participants
Stay on current antipsychotic medication for 12 weeks
Treatment as Usual: Current antipsychotic medication for 12 weeks
|
Total
n=39 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
36.1 years
STANDARD_DEVIATION 12.0 • n=99 Participants
|
39.8 years
STANDARD_DEVIATION 11.2 • n=107 Participants
|
37.8 years
STANDARD_DEVIATION 11.6 • n=206 Participants
|
|
Sex: Female, Male
Female
|
5 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
9 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
16 Participants
n=99 Participants
|
14 Participants
n=107 Participants
|
30 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Caucasian
|
8 Participants
n=99 Participants
|
9 Participants
n=107 Participants
|
17 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
African American
|
9 Participants
n=99 Participants
|
10 Participants
n=107 Participants
|
19 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Other
|
4 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
4 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
21 participants
n=99 Participants
|
18 participants
n=107 Participants
|
39 participants
n=206 Participants
|
PRIMARY outcome
Timeframe: 12 weeksThe Timeline Follow Back (TLFB) scale is used to measure weekly substance use for alcohol, marijuana, cocaine, and/or heroin by assessing the number of days a person used substances in the past week, on a scale from 0 to 7 \[0 = no substances that week; 7 = substance use every day\]. The outcome measure was the number of days per week that participants used a substance. If participants use more than one substance, only the primary substance (one used mostly frequently) was analyzed. While the TLFB was assessed weekly, the outcome measure reported is the change in substance use between Week 0 (Baseline) and Week 12 (End of Study). A decrease in number of days/week that substances were used indicates an improved (better) outcome. While the TLFB was assessed weekly, the outcome measure reported is the change in substance use between Week 0 (Baseline) and Week 12 (End of Study). A decrease in number of days/week that substances were used indicates an improved (better) outcome.
Outcome measures
| Measure |
Experimental
n=21 Participants
Brexpiprazole 4mg daily for 12 weeks
Brexpiprazole: Brexpiprazole 4mg daily for 12 weeks
|
Treatment as Usual
n=18 Participants
Stay on current antipsychotic medication for 12 weeks
Treatment as Usual: Current antipsychotic medication for 12 weeks
|
|---|---|---|
|
Timeline Follow Back (TLFB)
|
-1.765 score on a scale
Interval -3.117 to -0.413
|
-.532 score on a scale
Interval -1.91 to 0.846
|
PRIMARY outcome
Timeframe: 12 weeksThe Visual Analog Scale (VAS) measures substance craving. Subjects will make a mark on an unlabeled 100-millimeter line indicating their desire to use a particular substance over the past 7-days. A score of 0 indicates no desire to use and 100 indicating the strongest desire to use possible. The assessment was done weekly. Subjects reported craving for any substances they used that week with a separate mark for each substance (e.g., a mark for alcohol craving and another mark for marijuana). For outcome measures, only the primary substance (the substance used most frequently, as determined by the Timeline Follow Back assessment) was included. While cravings were assessed weekly, only the change in craving from Week 0 (Baseline) to Week 12 (End of Study) is reported; a decreased score (reduction in cravings) represents an improved outcome.
Outcome measures
| Measure |
Experimental
n=21 Participants
Brexpiprazole 4mg daily for 12 weeks
Brexpiprazole: Brexpiprazole 4mg daily for 12 weeks
|
Treatment as Usual
n=18 Participants
Stay on current antipsychotic medication for 12 weeks
Treatment as Usual: Current antipsychotic medication for 12 weeks
|
|---|---|---|
|
Visual Analog Scale (VAS)
|
-33.421 score on a scale
Interval -49.305 to -17.536
|
-8.898 score on a scale
Interval -25.511 to 7.716
|
SECONDARY outcome
Timeframe: 12 weeksThe amount of money spent on substances over a 7-day period will also be recorded as part of each weekly visit. Decreased money spent on substances over a 7-day period will also be considered an improved outcome.
Outcome measures
| Measure |
Experimental
n=21 Participants
Brexpiprazole 4mg daily for 12 weeks
Brexpiprazole: Brexpiprazole 4mg daily for 12 weeks
|
Treatment as Usual
n=18 Participants
Stay on current antipsychotic medication for 12 weeks
Treatment as Usual: Current antipsychotic medication for 12 weeks
|
|---|---|---|
|
Amount of Money Spent on Substances
|
-20.974 dollars spent
Interval -51.647 to 9.7
|
14.605 dollars spent
Interval -16.497 to 45.707
|
SECONDARY outcome
Timeframe: 12 WeeksThe Positive and Negative Symptom Scale (PANSS) is a measure used to assess symptom severity in patients with schizophrenia. Each item (symptom) is scored on a 7-point scale (1 = absent and 7 = extreme). The minimum and maximum values for the total 30 items (PANSS Total Score) are 30 and 210 respectively. Higher scores represent higher levels of psychiatric symptoms (worse outcomes). The PANSS has three subscales: "Positive" (measuring positive symptoms), "Negative" (measuring negative symptoms), and "General Psychopathology" (measuring general psychiatric symptoms). There are 7 items each for Positive and Negative subscales (minimum value for each is 7, and maximum value is 49), and 16 items for General Psychopathology (minimum value is 16 and maximum is 112). This study looked at changes in all 3 subscales and the PANSS total score between Week 0 (Baseline) and Week 12 (End of Study), with a decrease in score indicating improved psychiatric functioning.
Outcome measures
| Measure |
Experimental
n=21 Participants
Brexpiprazole 4mg daily for 12 weeks
Brexpiprazole: Brexpiprazole 4mg daily for 12 weeks
|
Treatment as Usual
n=18 Participants
Stay on current antipsychotic medication for 12 weeks
Treatment as Usual: Current antipsychotic medication for 12 weeks
|
|---|---|---|
|
Positive and Negative Symptom Scale (PANSS)
|
-3.690 score on a scale
Interval -9.188 to 1.807
|
-.274 score on a scale
Interval -5.996 to 5.447
|
SECONDARY outcome
Timeframe: 12 WeeksThe Clinical Global Impression - Severity (CGI-S) measures illness severity on a 7-point Likert scale, with a higher score indicating higher illness severity and worse outcomes (1 = "Normal, not at all ill" and 7 = "Among the most extremely ill patients"). The outcome measure for this study looked at the change in the CGI-S score between Week 0 (Baseline) and Week 12 (end of study), with a reduction in score indicating improved outcomes.
Outcome measures
| Measure |
Experimental
n=21 Participants
Brexpiprazole 4mg daily for 12 weeks
Brexpiprazole: Brexpiprazole 4mg daily for 12 weeks
|
Treatment as Usual
n=18 Participants
Stay on current antipsychotic medication for 12 weeks
Treatment as Usual: Current antipsychotic medication for 12 weeks
|
|---|---|---|
|
Clinical Global Impression - Severity
|
-.320 score on a scale
Interval -0.601 to -0.038
|
-.128 score on a scale
Interval -0.413 to 0.156
|
SECONDARY outcome
Timeframe: 12 WeeksThe Heinrichs Carpenter Quality of Life Scale (QOL)is a 21-item scale providing information on symptoms and functioning in patients with schizophrenia. Items are scored on a 0-6 scale, with 0 being no evidence of that item (e.g., social relationships are virtually absent) and 6 being adequate evidence of that item (e.g., adequate social relationships). Two items (#1 - "Intimate relationship with household members" and # 12 - "Satisfaction with occupational role functioning") are scored a "9" if the item is not applicable (e.g., lives alone with no close family or does not have an occupational role). Therefore, total scores can range from 0 to 132 (if 9s are scored). A higher total score indicates better psychosocial functioning. For this study, the outcome measure looked at the change in total score between Week 0 and Week 12.
Outcome measures
| Measure |
Experimental
n=21 Participants
Brexpiprazole 4mg daily for 12 weeks
Brexpiprazole: Brexpiprazole 4mg daily for 12 weeks
|
Treatment as Usual
n=18 Participants
Stay on current antipsychotic medication for 12 weeks
Treatment as Usual: Current antipsychotic medication for 12 weeks
|
|---|---|---|
|
Heinrichs Carpenter Quality of Life Scale (QOL)
|
4.049 score on a scale
Interval -1.95 to 10.049
|
-5.146 score on a scale
Interval -11.293 to 1.001
|
Adverse Events
Experimental
Treatment as Usual
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Experimental
n=21 participants at risk
Brexpiprazole 4mg daily for 12 weeks
Brexpiprazole: Brexpiprazole 4mg daily for 12 weeks
|
Treatment as Usual
n=18 participants at risk
Stay on current antipsychotic medication for 12 weeks
Treatment as Usual: Current antipsychotic medication for 12 weeks
|
|---|---|---|
|
Gastrointestinal disorders
Diarrhea
|
9.5%
2/21 • Number of events 2 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
|
0.00%
0/18 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
|
|
General disorders
Fatigure/Tiredness
|
14.3%
3/21 • Number of events 3 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
|
0.00%
0/18 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
|
|
General disorders
Dizziness
|
9.5%
2/21 • Number of events 2 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
|
|
General disorders
Cold-like symptoms
|
9.5%
2/21 • Number of events 2 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
|
16.7%
3/18 • Number of events 3 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
|
|
General disorders
Trouble Sleeping
|
9.5%
2/21 • Number of events 2 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
|
0.00%
0/18 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
|
|
General disorders
Nausea
|
14.3%
3/21 • Number of events 3 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
|
11.1%
2/18 • Number of events 2 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
|
|
General disorders
Restlessness/Irritability
|
4.8%
1/21 • Number of events 1 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place